Cochrane · systematic review · CD012862
Interventions for atypical haemolytic uraemic syndrome
Pugh, D, O'Sullivan, ED, Duthie, FAI, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 14 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Eculizumab versus placebo or alternative treatment for children and adults with atypical haemolytic uraemic syndrome (aHUS)
Population: children and adults with aHUS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death Eculizumab vs placebo or alternative treatment | no estimate extracted | 100 participants | Very low |
Requirement for KRT Eculizumab vs placebo or alternative treatment | no estimate extracted | 100 participants | Very low |
Disease remission Eculizumab vs placebo or alternative treatment | no estimate extracted | 100 participants | Very low |
Change in eGFR Eculizumab vs placebo or alternative treatment | no estimate extracted | 88 participants | Very low |
HRQoL Eculizumab vs placebo or alternative treatment | no estimate extracted | 100 participants | Very low |
Adverse events Eculizumab vs placebo or alternative treatment | no estimate extracted | 100 participants | Very low |
Meningococcal infection Eculizumab vs placebo or alternative treatment | no estimate extracted | 100 participants | Very low |
Ravulizumab versus placebo or alternative treatment for adults with atypical haemolytic uraemic syndrome (aHUS)
Population: adults with aHUS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death Ravulizumab vs placebo or alternative treatment | no estimate extracted | 58 participants | Very low |
Requirement for KRT Ravulizumab vs placebo or alternative treatment | no estimate extracted | 56 participants | Very low |
Disease remission Ravulizumab vs placebo or alternative treatment | no estimate extracted | 56 participants | Very low |
Change in eGFR Ravulizumab vs placebo or alternative treatment | no estimate extracted | 56 participants | Very low |
HRQoL Ravulizumab vs placebo or alternative treatment | no estimate extracted | 44 participants | Very low |
Adverse events Ravulizumab vs placebo or alternative treatment | no estimate extracted | 58 participants | Very low |
Meningococcal infection Ravulizumab vs placebo or alternative treatment | no estimate extracted | 58 participants | Very low |